107 results on '"LEWIS, ELDRIN F."'
Search Results
2. Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Non-Dialysis Chronic Kidney Disease Patients: A Post Hoc Regional Analysis of the PRO2TECT Randomized Clinical Trial of ESA-Treated Patients
3. Safety Endpoints With Vaadustat Versus Darbepoetin Alfa in Nondialysis CKD Patients: A Post hoc Regional Analysis of the PRO2TECT Randomized Clinical Trial of ESA-Naïve Patients
4. DISABILITIES REPORTING IN CLINICAL TRIALS. HOW ARE WE DOING?
5. WHO ARE WE MISSING? REPORTING OF TRANSGENDER AND GENDER EXPANSIVE POPULATIONS IN CLINICAL TRIALS
6. Treatment Differences in Medical Therapy for Heart Failure With Reduced Ejection Fraction Between Sociodemographic Groups
7. Functional and Symptomatic Clinical Trial Endpoints
8. The trial to assess chelation therapy 2 (TACT2): Rationale and design
9. Prognostic Impact of Cardiovascular Versus Noncardiovascular Hospitalizations in Heart Failure With Preserved Ejection Fraction: Insights From TOPCAT
10. Prevalence of cardiovascular diseases in COVID-19 related mortality in the United States
11. Health System–Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction: Results From the CONNECT-HF Trial
12. 2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19
13. Cardiac structure and function and quality of life associations in HFpEF: An analysis from TOPCAT-Americas
14. FUNCTIONAL AND SYMPTOMATIC CLINICAL ENDPOINTS IN HEART FAILURE RESEARCH: INSIGHTS FROM THE HEART FAILURE COLLABORATORY (HFC) - ACADEMIC RESEARCH CONSORTIUM (ARC) SCIENTIFIC EXPERT PANEL
15. Race and Ethnicity in Heart Failure
16. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics
17. Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function
18. Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium
19. Associations Between Depressive Symptoms and HFpEF-Related Outcomes
20. Differential Outcomes With Edetate Disodium-Based Treatment Among Stable Post Anterior vs. Non-Anterior Myocardial Infarction Patients
21. Conduct of Clinical Trials in the Era of COVID-19
22. IMPROVE-IT
23. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction
24. Exploring differences between patients who accept, decline, and are deemed ineligible for left ventricular assist device implantation as destination therapy
25. Endpoints in Heart Failure Drug Development
26. Reply
27. Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF
28. Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure
29. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction
30. Lung Ultrasound in Acute Heart Failure
31. Prior and Incident Myocardial Infarction in HFpEF: A Pooled, Patient-Level Analysis of 3 Contemporary Clinical Trials with 8,916 Patients
32. Influence of Age on the Efficacy and Safety of Spironolactone in Heart Failure with Preserved Ejection Fraction
33. QuaLVAD Instrument: A New Measure of Quality of Life in Patients with a Left Ventricular Assist Device (LVAD)
34. Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction
35. UTILITY OF BASELINE AND FOLLOW-UP CARDIOVASCULAR PHYSICAL EXAMS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: TOPCAT
36. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
37. PROGNOSTIC IMPLICATIONS OF BASELINE AND FOLLOW-UP CARDIOVASCULAR PHYSICAL EXAMS IN A CONTEMPORARY TRIAL OF PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION: PARADIGM-HF
38. Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease
39. Caregivers of Patients Considering a Destination Therapy Left Ventricular Assist Device and a Shared Decision-Making Intervention
40. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction
41. Sudden Death in Heart Failure With Preserved Ejection Fraction
42. African Americans Are Less Likely to Receive Care by a Cardiologist During an Intensive Care Unit Admission for Heart Failure
43. Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial
44. Pulmonary Congestion by Lung Ultrasound in Ambulatory Patients With Heart Failure With Reduced or Preserved Ejection Fraction and Hypertension
45. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
46. Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT)
47. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD
48. Influence of LVEF History on Functional Capacity and Quality of Life in Mid-Range EF
49. Orthopnea is Frequently Under-Reported in Routine Visits Despite its Impact on Quality of Life
50. Impact of continuous positive airway pressure and oxygen on health status in patients with coronary heart disease, cardiovascular risk factors, and obstructive sleep apnea: A Heart Biomarker Evaluation in Apnea Treatment (HEARTBEAT) analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.